Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP

NCT05074472 is registered in ClinicalTrials.gov with ZielBio, Inc. as lead sponsor.

NCT NCT05074472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP
Lead sponsor
ZielBio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 14, 2022
Completion date
September 30, 2023
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer metastatic, ovarian serous adenocarcinoma, ovarian serous cystadenocarcinoma, pancreatic ductal; adenocarcinoma, solid tumor, adult